<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124405</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0299</org_study_id>
    <nct_id>NCT05124405</nct_id>
  </id_info>
  <brief_title>Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices</brief_title>
  <official_title>Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the use of a continuous activity and heart rate tracker (Fitbit) and continuous&#xD;
      glucose monitor (CGM) in monitoring daily exercise-related activities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To evaluate the feasibility of a CGM-based physical activity intervention that includes the&#xD;
      use of CGM and FitbitÂ®.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To examine changes in physical activity motivation and other related psychosocial variables&#xD;
      (e.g., intention, perceived benefits, outcome expectancy) before and after the intervention.&#xD;
&#xD;
      Exploratory objective:&#xD;
&#xD;
      Examine cancer-related biomarkers and their associations with daily glucose pattern.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 24, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the feasibility of the PA intervention that features the use of CGM through the following criteria: CGM-specific refusal rate &lt;20% at the participant recruitment phase and protocol adherence rates &gt;80% at the end of the monitoring period.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Cancer</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Heart Rate Tracker (Fitbit)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous heart rate activity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Glucose Monitor (CGM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>monitoring daily exercise-related activities</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fitbit</intervention_name>
    <description>wearable activity tracker</description>
    <arm_group_label>Continuous Glucose Monitor (CGM)</arm_group_label>
    <arm_group_label>Heart Rate Tracker (Fitbit)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continuous Glucose Monitor</intervention_name>
    <description>wearable activity tracker</description>
    <arm_group_label>Continuous Glucose Monitor (CGM)</arm_group_label>
    <arm_group_label>Heart Rate Tracker (Fitbit)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women at least 18 years old&#xD;
&#xD;
          -  Body mass index (BMI) 25 kg/m2&#xD;
&#xD;
          -  Engage in less than 150 minutes of moderate-intensity PA per week in the past month&#xD;
&#xD;
          -  Capable of participating in moderate-vigorous unsupervised exercise (as determined by&#xD;
             the Physical Activity Readiness Questionnaire (PARQ) or a medical release from their&#xD;
             physician)&#xD;
&#xD;
          -  Self-reported ability to walk one block without pain or discomfort&#xD;
&#xD;
          -  Have a smart phone with daily internet access that is compatible with the LibreLink&#xD;
             app&#xD;
&#xD;
          -  Ability to speak, read, and write in English&#xD;
&#xD;
          -  For the cancer survivor cohort (participant accession number #21 and beyond),&#xD;
             individuals must have been diagnosed with stage I-III breast or colorectal cancer and&#xD;
             completed adjuvant therapy (i.e., chemo and/or radiation therapy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Self-reported current diagnosis or history of type 1 diabetes or type 2 diabetes&#xD;
&#xD;
          -  Self-reported use of oral antidiabetic agents (OADs)&#xD;
&#xD;
          -  Previous or current treatment with any insulin regimen other than basal insulin, e.g.&#xD;
             prandial or pre-mixed insulin (short term treatment due to intercurrent illness&#xD;
             including gestational is allowed at the discretion for the investigator)&#xD;
&#xD;
          -  Current use of a continuous glucose monitor&#xD;
&#xD;
          -  Fasting glucose &gt; 125 mg/dL&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Self-reported health issues that limit physical activity&#xD;
&#xD;
          -  On dialysis&#xD;
&#xD;
          -  Work overnight shifts&#xD;
&#xD;
          -  Unwilling to use CGM&#xD;
&#xD;
          -  Current participation in other wellness or weight loss-related program or intervention&#xD;
&#xD;
          -  Currently on a low-carb diet&#xD;
&#xD;
          -  Unable to receive REDCap survey through their mobile phones&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Basen-Engquist, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

